SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending amid significant price volatility, with community chatter focused on identifying the bottom and anticipating the next launch catalyst. Concerns around potential delays and market manipulation are contrasted by bullish arguments highlighting institutional ownership and long-term potential in the space-based mobile network sector. Investors are closely watching for company announcements and launch dates to drive future price movement.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending amid discussions about the potential impact of SNAP benefit suspensions due to the government shutdown, with community members debating whether this will significantly hurt the retailer. Recent earnings and future guidance are also hot topics, alongside Walmart's strengths as a consumer staple during uncertain economic times. Additionally, the stock's technical patterns, like head and shoulders formations, are being analyzed for potential trading strategies.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's post-earnings stock movement is driving intense discussion, with the community debating whether concerns of an AI bubble are justified despite strong earnings and guidance. Some believe the sell-off is tied to broader market weakness and crypto liquidations, while others point to potential accounting issues or an impending recession. Despite varied opinions, analysts generally remain bullish, with many reiterating "Outperform" ratings.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation around potential acquisition bids, particularly with a deadline approaching, fueling community discussion about possible outcomes and deal prices. Massive blocks of purchases are being noted, with chatter focusing on potential market manipulation and the involvement of key players like Comcast and Paramount Skydance.  News of HBO renewing a Game of Thrones series has also sparked some positive sentiment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending downwards as community members discuss concerns around potential market manipulation and an AI bubble, especially following earnings. Traders are debating whether to buy the dip or prepare for a larger correction, while monitoring key support levels. Some are pointing to macro factors like interest rate expectations and geopolitical concerns as potential catalysts for further volatility.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss the stock's continued decline despite positive developments, including licensing its autonomous driving chip. Community sentiment is mixed, with some expressing frustration and calling for action, while others remain hopeful and see the low price as a buying opportunity. Some investors speculate about market manipulation and the potential for a short squeeze, while others see a bleak future ahead.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as the community debates whether its recent surge is overextended, despite a UBS price target boost. The stock's movements are tied to the broader AI narrative, particularly rising memory prices and potential supply constraints driven by demand for AI data centers. Traders are closely watching for management comments at an upcoming conference and Nvidia's earnings report for further catalysts.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about a potential market bottom and the influence of large institutional players. Community discussions revolve around whether this dip presents a buying opportunity or signals a deeper correction, with some pointing to macro factors and potential liquidations as drivers. Sentiment is mixed, with bullish and bearish arguments clashing amidst the price swings.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending due to market volatility following mixed earnings reports from major tech companies and uncertainty surrounding interest rates and trade relations. Traders are actively discussing potential support and resistance levels, as well as strategies for navigating the current market swings. The overall sentiment appears cautiously optimistic, with many anticipating a potential rebound.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing heavy volatility, sparking discussions about a potential market correction and whether dip-buying strategies will continue to pay off. Some community members are pointing to broader macroeconomic concerns and the influence of crypto markets, while others are eyeing key support levels for potential reversals. The conversation highlights uncertainty around near-term market direction.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brokers Set Expectations for Fractyl Health FY2025 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Fractyl Health in a report issued on Thursday, November 13th. HC...

Fractyl Health (NASDAQ:GUTS) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Fractyl Health (NASDAQ:GUTS - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus...

Preview: Fractyl Health's Earnings

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated with its Revita lost an additional 2.5% of their total body weight at three months in a trial. At the time of writing, shares of the company traded 28% higher on Friday afternoon.The study was designed to evaluate the Revita procedure in adults with obesity who achieved at least 15% total body weight loss with Tirzepatide, the active ingredient in Eli Lilly’s blockbuster weight loss drug Zepbound. Those who received a sham procedure after discontinuing Zepbound regained 10% total body weight in the study at three months, the company said.Revita is Fractyl’s lead product candidate. The procedure is designed to reverse damage to intestinal nutrient-sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets by remodeling the inner wall of the first part of the small intestine.“These results are clinically and statistically significant and provide randomized, blinded evidence that drug-free, durable weight maintenance is possible,” the company said, while adding that the study also supports Revita in post-GLP-1 weight maintenance.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156942/0/en/Fractyl-Health-Announces-Groundbreaking-Data-from-REMAIN-1-Midpoint-Cohort-Showing-Revita-Maintained-Weight-Loss-After-GLP-1-Discontinuation.html">stated</a> that no serious adverse events related to Revita were identified in the study, and side effects were infrequent and mild. The firm expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.On Friday, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156951/0/en/Fractyl-Health-Announces-Pricing-of-60-Million-Underwritten-Offering-of-Common-Stock.html">announced</a> the pricing of an underwritten offering of 60 million shares of its common stock at $1.00 per share, representing a discount of about 1% from the stock’s closing price on Thursday. The gross proceeds from the offering are expected to be about $60 million, the company added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GUTS">GUTS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_26_at_1_00_54_PM_png_90a4342a59.webp" alt="GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment at the offering.<stembedurl>https://stocktwits.com/Stmkr/message/630122910</stembedurl>GUTS stock is down 38% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-reportedly-expects-non-restaurant-deliveries-to-surge-faster-than-previously-expected/chDVlUmR3eW">Uber Reportedly Expects Non-Restaurant Deliveries To Surge Faster Than Previously Expected</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GUTS Stock Rallied About 28% Today – Here’s Why

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.

Equity

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.


Fractyl Health shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants.&nbsp;The offering includes accompanying common warrants, and Ladenburg Thalmann is acting as&nbsp;the sole book-running manager.Despite the market’s negative reaction to the capital raise, retail sentiment on Stocktwits remained optimistic, buoyed&nbsp;by the release of strong new clinical data hours earlier.&nbsp;The company shared two-year follow-up results from the Germany Real-World Registry study, which evaluated the Revita procedure in people with obesity and advanced type 2 diabetes (T2D) who had inadequately controlled glucose levels despite being on up to three glucose-lowering agents (GLAs).According to the study, a single Revita procedure led to a median weight loss of 9.6%, sustained over two years, with weight decreasing from 104 kg to 97 kg at year one and remaining stable through year two.&nbsp;Notably, 7 of 8 participants achieved at least a 5% weight reduction, and 5 of 8 saw reductions of 10% or more. Only one participant, who had a history of cortisone therapy known to cause weight gain, experienced&nbsp;a modest weight increase.Meanwhile, median HbA1c decreased from 9.6% to 7.2%, which was maintained over two years of follow-up. Patients were also able to reduce or stabilize the dosing of GLAs, and there were no device or procedure-related serious adverse events.Fractyl said the findings support the potential of Revita as a long-lasting, non-drug metabolic therapy and build momentum for its ongoing U.S. pivotal trial, REMAIN-1, which is under an IDE and is designed to assess Revita for weight maintenance after GLP-1 treatment.&nbsp;The company expects Midpoint Cohort data in the third quarter and primary endpoint data from the Pivotal Cohort in the second half of&nbsp; 2026.As of now, 34 patients are enrolled in the Germany registry, which is no longer recruiting but will continue with protocol-defined follow-up. Weight loss and glycemic benefits were observed as early as one month post-procedure and persisted throughout the study duration.Fractyl intends to use net proceeds from the offering, along with existing cash, to support both the Revita and Rejuva pipeline programs, and for working capital and general corporate purposes.On Stocktwits,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">retail sentiment for Fractyl</a> was ‘extremely bullish’ amid a 124% surge in 24-hour message volume.One user said the strong two-year Revita data was a “big win” and that similar setups, including positive clinical news followed by a quick offering, have historically seen shares recover to pre-offering levels.&nbsp;While the user noted the company “could have done the PR’ing/offering a bit better,” they added the underlying science was “phenomenal” and called Revita a “first-in-class” product with major potential.<stembedurl>https://stocktwits.com/BioRich/message/623885253</stembedurl>Another user said they were buying into Fractyl, looking for either a short squeeze or a potential buyout.<stembedurl>https://stocktwits.com/garygb/message/623881828</stembedurl>Fractyl’s stock has declined 12.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Fractyl Health (GUTS) shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants. (Photo credit: Getty Images)

Fractyl Health Sinks After-Hours On Stock Offering, But Investors Cheer Durable Weight Loss Data

Retail optimism surged following new real-world data showing that patients with advanced type 2 diabetes sustained weight loss and glycemic improvements two years after a single Revita procedure.

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...

Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Current Price	$1.30
Prev Close	$1.33
Open	$1.38
Dividend Yield	0.00%
50-Day Moving Average	$1.24
Beta	1.11
Avg. Volume	2.5M
PE Ratio	-0.59

52-Week High	$3.03
52-Week Low	$0.825
Market Capitalization	$182.27M
EPS (Annual)	-$1.44
Price to Book	-55.32
Revenue Per Employee	$869.16
Enterprise Value/EBITDA	N/A

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GUTS News

GUTSFractyl Health Inc.